One of them is flibanserin, a 5HT1a agonist and a 5HT2a antagonist, which has been demonstrated to increase sexual desire, reduce sexual dysfunction-associated discomfort, and improve sexual activity in premenopausal women with low sexual desire, with a good tolerability [34, 35], which translated into flibanserin being approved in the US [36]. The gene discussed is HTR1A; the disease is sexual dysfunction.